|
Market Closed -
Other stock markets
|
After hours 05:26:10 am | |||
| 56.55 USD | -0.39% |
|
56.72 | +0.29% |
| 21/05 | Health Care Up as Biotech Rallies on Risk Appetite -- Health Care Roundup | DJ |
| 21/05 | BioMarin's drug shows significant growth gains in children in late-stage trial | RE |
Evolution of the Average Target: BioMarin Pharmaceutical Inc.
Evolution of the Target Price: BioMarin Pharmaceutical Inc.
Changes in Analyst Recommendations: BioMarin Pharmaceutical Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +55.34% | |||||
| +36.31% | |||||
| +10.67% | |||||
| +69.34% | |||||
| +44.18% | |||||
| +14.02% | |||||
| +7.92% | |||||
| -9.03% | |||||
| +6.23% | |||||
| +60.5% | |||||
| Average | +29.55% | |||||
| Weighted average by Cap. | +29.89% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Morgan Stanley | |
| Oppenheimer | |
| Canaccord Genuity | |
| Truist Securities | |
| Leerink Partners | |
| Stifel Nicolaus | |
| RBC Capital Markets | |
| HC Wainwright | |
| UBS | |
| BofA Securities | |
| Wolfe Research | |
| William Blair & Co. | |
| Baird | |
| Scotiabank | |
| Wells Fargo Securities | |
| Wedbush | |
| BMO Capital | |
| Barclays | |
| Cantor Fitzgerald | |
| Bernstein | |
| Citigroup | |
| Piper Sandler | |
| Guggenheim | |
| Credit Suisse | |
| SVB Securities LLC | |
| Jefferies & Co. | |
| JPMorgan Chase | |
| Goldman Sachs | |
| SVB Leerink | |
| Evercore ISI |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BMRN Stock
- Consensus BioMarin Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition